文献速递先天性心脏病外科心外重症与机械循环支持

儿童心脏移植候选者脱敏治疗阳性反应的影响因素与预测因子

Impact and predictors of positive response to desensitization in pediatric heart transplant candidates.
PubMed 文献 · J Heart Lung Transplant · 2019-08-25

该回顾性研究评估了儿童心脏移植候选者脱敏治疗的疗效及预测因素。脱敏治疗组中8例(62%)出现阳性反应,且应答者接受更多剂量的静脉注射免疫球蛋白(IVIG)(8 vs 2,p<0.05)。抗HLA I类抗体与非应答显著相关(p=1.9×10-4),而同种移植物联合心室辅助装置比单独任一因素更具致敏性(p=3.1×10-4)。

要点

  • 儿童心脏移植致敏候选者脱敏治疗阳性反应率为62%。
  • IVIG剂量与脱敏应答相关,应答者接受更多剂量(8 vs 2)。
  • 抗HLA I类抗体是脱敏无应答的重要影响因素。

核心结论

  • 多数接受脱敏治疗的儿童心脏移植候选者出现有利反应,IVIG呈剂量依赖性反应。
  • 抗HLA类别可能影响脱敏治疗反应,而传统致敏危险因素对反应无影响。

研究设计与样本

  • 回顾性研究,纳入2013年1月1日至2018年6月30日在本机构登记的儿童心脏移植候选者。
  • 致敏定义为计算群体反应性抗体(cPRA)≥10%且至少1个强阳性抗体。
  • 脱敏反应定义为在等待名单移除、心脏移植或死亡前随访面板反应性抗体(PRA)检测中,≥90%的强阳性抗体平均荧光强度(MFI)降低≥25%(13例患者有数据)。
  • 候选者分为致敏接受脱敏治疗组(ST,n=14)、致敏未接受治疗组(SNT,n=18)和非致敏组(n=55)。

主要发现

  • 脱敏治疗组中8例(62%)在重复PRA检测时出现脱敏反应。
  • 脱敏应答者接受的IVIG剂量更多(8 vs 2,p<0.05)。
  • 非应答者的抗HLA I类抗体特别耐药(p=1.9×10-4)。
  • 同种移植物联合心室辅助装置的致敏性高于单独任一因素(p=3.1×10-4)。
  • 上述致敏危险因素未影响脱敏反应。

临床怎么用

  • 儿童心脏移植致敏候选者可考虑脱敏治疗,尤其关注IVIG剂量。
  • 抗HLA I类抗体阳性的致敏患者可能对脱敏治疗反应较差。
  • 同种移植物联合心室辅助装置的患者致敏风险更高,但不应因此排除脱敏治疗。

局限性

  • 回顾性单中心研究,样本量有限。
  • 脱敏反应数据仅13例患者可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Desensitization, the process of reducing anti-human leukocyte antigen (HLA) antibodies in sensitized patients awaiting heart transplantation (HT), has unclear efficacy in pediatric HT candidates. METHODS: Pediatric HT candidates listed at our institution between January 1, 2013 and June 30, 2018 were retrospectively evaluated. Sensitization was defined as the calculated panel reactive antibody (cPRA) ≥ 10% with ≥ 1 a strong positive antibody. The desensitization response was defined as a ≥ 25% reduction in the mean fluorescence intensity (MFI) for ≥ 90% of the strong positive antibodies on follow-up panel reactive antibody (PRA) testing before waitlist removal, HT, or death (data available for 13 patients). RESULTS: The HT candidates were categorized as sensitized receiving desensitization therapy (ST, n = 14), sensitized not receiving therapy (SNT, n = 18), or non-sensitized (n = 55). A desensitization response was observed in 8 (62%) of the ST upon repeat PRA testing, with the ST responders receiving more doses of intravenous immunoglobulin (IVIG) (8 vs 2, p < 0.05). The anti-HLA class I antibodies were particularly resistant for non-responders (p = 1.9 × 10-4). The combination of homograft and ventricular assist device was more sensitizing than either alone (p = 3.1 × 10-4). However, these sensitization risk factors did not impact the desensitization response. The ST was associated with a higher likelihood of remaining listed and a longer waitlist time without substantially impacting the HT rate, waitlist mortality, or early post-HT outcomes. CONCLUSIONS: Most ST patients had a favorable response to desensitization, with a dose-dependent response observed for IVIG. The anti-HLA class likely impacts the ST response, whereas traditional sensitization risk factors had no impact on the response.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Edwards JJ, Seliktar N, White R, et al. Impact and predictors of positive response to desensitization in pediatric heart transplant candidates. J Heart Lung Transplant. 2019. PMID: 31672220. doi:10.1016/j.healun.2019.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。